Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Mutations in the enzyme cytosolic isocitrate dehydrogenase 1 (IDH1) are commonly found in glioblastomas, a major subset of primary human brain cancers. However, only a single copy of the gene is mutated, suggesting that the mutation does not result in a simple loss of function. Here, IDH1 mutations are shown to act in a gain-of-function manner, resulting in a new ability of the enzyme to catalyse α-ketoglutarate to R(-)-2-hydroxyglutarate, an onco-metabolite.